17,261 trials
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
Neuroendocrine Tumors
Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants
Schizophrenia
Primary: Change From Baseline in the Composite Score of Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)…
Anemia · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Best Overall Response Rate as Determined by International Working Group Criteria — 28.6 percentage of patients with CR, PR or CI
Diffuse Large B-Cell Lymphoma
Primary: Number of Patients With a Complete Response — 7 Participants
Recurrent Melanoma · Stage IV Skin Melanoma
Primary: Overall Objective Response — 3; 3; 6 Participants
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
Opioid Abuse · Opioid Addiction · Stimulant Abuse
Primary: Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test — 87; 87.5; 90 percent of correct response
Stage III Vulvar Cancer · Stage IVB Vulvar Cancer · Vulvar Squamous Cell Carcinoma
Primary: Complete Clinical and Pathologic Response — 50 Percentage of Participants
Cocaine Dependence
Primary: Number of Choices to Self-administer Cocaine (Out of 5 Choices) — 1.61; 4.33 number of cocaine choices
HIV Infections
Primary: Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment. — 0.17; 0.1; 0.19 proportion of participants
HER-2 Positive Breast Cancer
Primary: Intracranial Objective Response Rate- Modified RECIST Criteria — 0; 1; 17; 8 Participants
Crohn's Disease
Primary: Adjudicated Potential Cardiovascular Events — 0 Number of events meeting criteria
Ischaemic Attack, Transient
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 11; 6; 8; 6 Participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) (Part A) — 0; 0 Participants